Accent Therapeutics Stock Price, Funding, Valuation, Revenue ...

Jan 23, 2024 · Funding, Valuation & Revenue. 3 Fundings. Accent Therapeutics has raised $178M over 3 rounds.. Accent Therapeutics's latest funding round was a Series C for $75M on …

CouponFollow Extension

$178
OFF

Accent Therapeutics Stock Price, Funding, Valuation, Revenue ...

6 days from now

Jan 23, 2024 · Funding, Valuation & Revenue. 3 Fundings. Accent Therapeutics has raised $178M over 3 rounds.. Accent Therapeutics's latest funding round was a Series C for $75M on …

cbinsights.com

$178
OFF

Accent Therapeutics - Raised $178M Funding From 12 Investors

6 days from now

Oct 27, 2024 · Accent Therapeutics has raised a total funding of $178M over 3 rounds from 12 investors. Investors include Atlas Venture, Google Ventures and 10 others. ... How much …

tracxn.com

$75
OFF

Accent Therapeutics Announces $75 Million Series C Financing To …

6 days from now

Jan 23, 2024 · Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the completion of a $75 million …

yahoo.com

$75
OFF

Accent Therapeutics Announces $75 Million Series C Financing To …

6 days from now

Jan 23, 2024 · Financing led by Mirae Asset Capital Life Science with participation from additional new and existing investors Funds will support advancement of lead programs through early …

wpri.com

$75
OFF

Accent Therapeutics Raises $75M In Series C Funding Round

6 days from now

Jan 23, 2024 · Biopharmaceutical company Accent Therapeutics has raised $75 million in a series C financing round, with the aim of using the funds to advance two of its precision oncology …

labpulse.com

$75
OFF

Accent Therapeutics Announces $75 Million Series C Financing To …

6 days from now

Jan 23, 2024 · Financing led by Mirae Asset Capital Life Science with participation from additional new and existing investors. Funds will support advancement of lead programs through early …

prnewswire.com

$102
OFF

Synnovation’s $102m Round Heads Latest Biotech Financings

6 days from now

2 days ago · RNA specialist Accent Therapeutics has continued a healthy series of funding rounds, raising $75 million in a Series C that was led by Mirae Asset Capital Life Science and …

pharmaphorum.com

$75
OFF

Pharmas Back Accent’s Plan To Make RNA-targeting Cancer Drugs

6 days from now

Jan 23, 2024 · Accent Therapeutics has raised a $75 million Series C round, the company announced Tuesday in a sign of continued investor interest in chemical drugs that target RNA …

biopharmadive.com

$63
OFF

Accent Therapeutics Announces $63 Million Series B ... - Business …

6 days from now

Apr 23, 2020 · Since launching in 2018, Accent has advanced a broad pipeline of programs, including its two lead programs – METTL3 and ADAR1. METTL3 is an RNA methyltransferase …

businesswire.com

$110
OFF

858 Therapeutics Stock Price, Funding, Valuation, Revenue

6 days from now

Jul 11, 2024 · Funding, Valuation & Revenue. 4 Fundings. 858 Therapeutics has raised $110M over 4 rounds. 858 Therapeutics's latest funding round was a Series B for $50M on July 11, …

cbinsights.com

$63
OFF

Accent Therapeutics Bags $63M To Advance The Development Of Its...

6 days from now

Jan 14, 2022 · Fremont, CA: Accent Therapeutics, a Cambridge, Massachusetts-based biopharmaceutical company developing cutting edge treatments for cancer patients, has …

healthcaretechoutlook.com

FAQs about Accent Therapeutics Stock Price, Funding, Valuation, Revenue ... Coupon?

Does Accent Therapeutics have a series C financing?

LEXINGTON, Mass., Jan. 23, 2024 /PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the completion of a $75 million Series C financing. ...

When did Accent Therapeutics close?

Accent Therapeutics closed its last funding round on Jan 23, 2024 from a Series C round. Who are Accent Therapeutics's competitors? Alternatives and possible competitors to Accent Therapeutics may include Tessera Therapeutics , Soleno Therapeutics , and Zomedica. ...

Is Accent Therapeutics growing?

Accent Therapeutics may be growing as evidenced by the successful closure of a $75 million Series C financing round. This substantial capital infusion suggests that investors have confidence in the company's potential and may enable further research, development, and expansion of operations. ...

What is Accent Therapeutics' Series B financing?

LEXINGTON, Mass.-- ( BUSINESS WIRE )--Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, announced today that it has completed a $63 million Series B financing. ...

Is Accent Therapeutics a biopharmaceutical company?

Accent Therapeutics, Inc. operates as a biopharmaceutical company. The Company develops inhibitory molecule drugs in the field of epitranscriptomics. Accent Therapeutics offers its services in the State of New York. Trademarks Privacy Policy ©2024 Bloomberg L.P. All Rights Reserved. ...

Where is Accent Therapeutics located?

This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth and Where is Accent Therapeutics's headquarters? Accent Therapeutics is located in Lexington, Massachusetts, United States. ...